Please Wait.....
Report
Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 280 Pages I Allied Market Research
Spine Biologics Market
The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.
Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.
Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.
However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.
Segment Review
The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By product, the spinal allografts segment dominated the market in 2023.
As per end user, the hospital segment acquired a high stake in the market in 2023.
Region wise, North America is projected to be the highest revenue generator by 2035.
Competition Analysis
The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product
- Spinal Allografts
- Bone Graft Substitutes
- Cell-Based Matrix
By End User
- Hospitals
- Outpatient Facilities
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Stryker Corporation
- NuVasive, Inc.
- orthofix
- Johnson & Johnson
- Exactech, Inc
- Zimmer Biomet Holding, Inc.
- Arthrex, Inc.
- Medtronic plc
- Organogenesis Inc
- Kuros Biosciences
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: IMMUNOHEMATOLOGY MARKET, BY PRODUCT
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product
4.2. Analyzers And Systems
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Reagents
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: IMMUNOHEMATOLOGY MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Blood-related Diseases
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. HIV
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: IMMUNOHEMATOLOGY MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Hospitals
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Diagnostic Laboratories
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Others
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: IMMUNOHEMATOLOGY MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Product
7.2.3. Market Size and Forecast, By Application
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Immunohematology Market
7.2.6.1. Market Size and Forecast, By Product
7.2.6.2. Market Size and Forecast, By Application
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Immunohematology Market
7.2.7.1. Market Size and Forecast, By Product
7.2.7.2. Market Size and Forecast, By Application
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Immunohematology Market
7.2.8.1. Market Size and Forecast, By Product
7.2.8.2. Market Size and Forecast, By Application
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Product
7.3.3. Market Size and Forecast, By Application
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Immunohematology Market
7.3.6.1. Market Size and Forecast, By Product
7.3.6.2. Market Size and Forecast, By Application
7.3.6.3. Market Size and Forecast, By End User
7.3.7. France Immunohematology Market
7.3.7.1. Market Size and Forecast, By Product
7.3.7.2. Market Size and Forecast, By Application
7.3.7.3. Market Size and Forecast, By End User
7.3.8. UK Immunohematology Market
7.3.8.1. Market Size and Forecast, By Product
7.3.8.2. Market Size and Forecast, By Application
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Italy Immunohematology Market
7.3.9.1. Market Size and Forecast, By Product
7.3.9.2. Market Size and Forecast, By Application
7.3.9.3. Market Size and Forecast, By End User
7.3.10. Spain Immunohematology Market
7.3.10.1. Market Size and Forecast, By Product
7.3.10.2. Market Size and Forecast, By Application
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest of Europe Immunohematology Market
7.3.11.1. Market Size and Forecast, By Product
7.3.11.2. Market Size and Forecast, By Application
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Product
7.4.3. Market Size and Forecast, By Application
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Immunohematology Market
7.4.6.1. Market Size and Forecast, By Product
7.4.6.2. Market Size and Forecast, By Application
7.4.6.3. Market Size and Forecast, By End User
7.4.7. China Immunohematology Market
7.4.7.1. Market Size and Forecast, By Product
7.4.7.2. Market Size and Forecast, By Application
7.4.7.3. Market Size and Forecast, By End User
7.4.8. India Immunohematology Market
7.4.8.1. Market Size and Forecast, By Product
7.4.8.2. Market Size and Forecast, By Application
7.4.8.3. Market Size and Forecast, By End User
7.4.9. Australia Immunohematology Market
7.4.9.1. Market Size and Forecast, By Product
7.4.9.2. Market Size and Forecast, By Application
7.4.9.3. Market Size and Forecast, By End User
7.4.10. South Korea Immunohematology Market
7.4.10.1. Market Size and Forecast, By Product
7.4.10.2. Market Size and Forecast, By Application
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Immunohematology Market
7.4.11.1. Market Size and Forecast, By Product
7.4.11.2. Market Size and Forecast, By Application
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Product
7.5.3. Market Size and Forecast, By Application
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Immunohematology Market
7.5.6.1. Market Size and Forecast, By Product
7.5.6.2. Market Size and Forecast, By Application
7.5.6.3. Market Size and Forecast, By End User
7.5.7. Saudi Arabia Immunohematology Market
7.5.7.1. Market Size and Forecast, By Product
7.5.7.2. Market Size and Forecast, By Application
7.5.7.3. Market Size and Forecast, By End User
7.5.8. South Africa Immunohematology Market
7.5.8.1. Market Size and Forecast, By Product
7.5.8.2. Market Size and Forecast, By Application
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Immunohematology Market
7.5.9.1. Market Size and Forecast, By Product
7.5.9.2. Market Size and Forecast, By Application
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Bio-Rad Laboratories, Inc
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Werfen
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Grifols, S.A.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Danaher Corporation
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Siemens
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Thermo Fisher Scientific Inc.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Abbott Laboratories
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Merck KGaA
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. F. Hoffmann-La Roche Ltd
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Cardinal Health
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 2. SPINE BIOLOGICS MARKET FOR SPINAL ALLOGRAFTS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. SPINE BIOLOGICS MARKET FOR BONE GRAFT SUBSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. SPINE BIOLOGICS MARKET FOR CELL-BASED MATRIX, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 6. SPINE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. SPINE BIOLOGICS MARKET FOR OUTPATIENT FACILITIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. SPINE BIOLOGICS MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. NORTH AMERICA SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 10. NORTH AMERICA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 11. NORTH AMERICA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 12. U.S. SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 13. U.S. SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 14. CANADA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 15. CANADA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 16. MEXICO SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 17. MEXICO SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. EUROPE SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 19. EUROPE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 20. EUROPE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. GERMANY SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 22. GERMANY SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 23. FRANCE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 24. FRANCE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 25. UK SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 26. UK SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. ITALY SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 28. ITALY SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 29. SPAIN SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 30. SPAIN SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 31. REST OF EUROPE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 32. REST OF EUROPE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 34. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 35. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. JAPAN SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 37. JAPAN SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. CHINA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 39. CHINA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. AUSTRALIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 41. AUSTRALIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. INDIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 43. INDIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 44. SOUTH KOREA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 45. SOUTH KOREA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. REST OF ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 47. REST OF ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 48. LAMEA SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 49. LAMEA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 50. LAMEA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. BRAZIL SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 52. BRAZIL SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. SAUDI ARABIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 54. SAUDI ARABIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. SOUTH AFRICA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 56. SOUTH AFRICA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 57. REST OF LAMEA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 58. REST OF LAMEA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. STRYKER CORPORATION: KEY EXECUTIVES
TABLE 60. STRYKER CORPORATION: COMPANY SNAPSHOT
TABLE 61. STRYKER CORPORATION: OPERATING SEGMENTS
TABLE 62. STRYKER CORPORATION: PRODUCT PORTFOLIO
TABLE 63. STRYKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64. NUVASIVE, INC.: KEY EXECUTIVES
TABLE 65. NUVASIVE, INC.: COMPANY SNAPSHOT
TABLE 66. NUVASIVE, INC.: OPERATING SEGMENTS
TABLE 67. NUVASIVE, INC.: PRODUCT PORTFOLIO
TABLE 68. NUVASIVE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. ORTHOFIX: KEY EXECUTIVES
TABLE 70. ORTHOFIX: COMPANY SNAPSHOT
TABLE 71. ORTHOFIX: OPERATING SEGMENTS
TABLE 72. ORTHOFIX: PRODUCT PORTFOLIO
TABLE 73. ORTHOFIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 75. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 76. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 77. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 78. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. EXACTECH, INC: KEY EXECUTIVES
TABLE 80. EXACTECH, INC: COMPANY SNAPSHOT
TABLE 81. EXACTECH, INC: OPERATING SEGMENTS
TABLE 82. EXACTECH, INC: PRODUCT PORTFOLIO
TABLE 83. EXACTECH, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. ZIMMER BIOMET HOLDING, INC.: KEY EXECUTIVES
TABLE 85. ZIMMER BIOMET HOLDING, INC.: COMPANY SNAPSHOT
TABLE 86. ZIMMER BIOMET HOLDING, INC.: OPERATING SEGMENTS
TABLE 87. ZIMMER BIOMET HOLDING, INC.: PRODUCT PORTFOLIO
TABLE 88. ZIMMER BIOMET HOLDING, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. ARTHREX, INC.: KEY EXECUTIVES
TABLE 90. ARTHREX, INC.: COMPANY SNAPSHOT
TABLE 91. ARTHREX, INC.: OPERATING SEGMENTS
TABLE 92. ARTHREX, INC.: PRODUCT PORTFOLIO
TABLE 93. ARTHREX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 95. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 96. MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 97. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 98. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. ORGANOGENESIS INC: KEY EXECUTIVES
TABLE 100. ORGANOGENESIS INC: COMPANY SNAPSHOT
TABLE 101. ORGANOGENESIS INC: OPERATING SEGMENTS
TABLE 102. ORGANOGENESIS INC: PRODUCT PORTFOLIO
TABLE 103. ORGANOGENESIS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. KUROS BIOSCIENCES: KEY EXECUTIVES
TABLE 105. KUROS BIOSCIENCES: COMPANY SNAPSHOT
TABLE 106. KUROS BIOSCIENCES: OPERATING SEGMENTS
TABLE 107. KUROS BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 108. KUROS BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL SPINE BIOLOGICS MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF SPINE BIOLOGICS MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN SPINE BIOLOGICS MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSPINE BIOLOGICS MARKET
FIGURE 10. GLOBAL SPINE BIOLOGICS MARKET SEGMENTATION, BY PRODUCT
FIGURE 11. SPINE BIOLOGICS MARKET FOR SPINAL ALLOGRAFTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. SPINE BIOLOGICS MARKET FOR BONE GRAFT SUBSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. SPINE BIOLOGICS MARKET FOR CELL-BASED MATRIX, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL SPINE BIOLOGICS MARKET SEGMENTATION, BY END USER
FIGURE 15. SPINE BIOLOGICS MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. SPINE BIOLOGICS MARKET FOR OUTPATIENT FACILITIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 21. COMPETITIVE DASHBOARD
FIGURE 22. COMPETITIVE HEATMAP: SPINE BIOLOGICS MARKET
FIGURE 23. TOP PLAYER POSITIONING, 2023
FIGURE 24. STRYKER CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 25. STRYKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 26. STRYKER CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 27. NUVASIVE, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 28. NUVASIVE, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 29. NUVASIVE, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 30. ORTHOFIX: NET SALES, 2021-2023 ($BILLION)
FIGURE 31. ORTHOFIX: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. ORTHOFIX: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. EXACTECH, INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. EXACTECH, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. EXACTECH, INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. ZIMMER BIOMET HOLDING, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. ZIMMER BIOMET HOLDING, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. ZIMMER BIOMET HOLDING, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. ARTHREX, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. ARTHREX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. ARTHREX, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. MEDTRONIC PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. ORGANOGENESIS INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. ORGANOGENESIS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. ORGANOGENESIS INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. KUROS BIOSCIENCES: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. KUROS BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. KUROS BIOSCIENCES: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security